Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Breast Neoplasms | 89 | 2023 | 20822 | 4.960 |
Why?
|
Medicare | 77 | 2024 | 6566 | 4.890 |
Why?
|
Medicare Part D | 14 | 2023 | 328 | 4.180 |
Why?
|
Health Expenditures | 25 | 2023 | 2348 | 3.980 |
Why?
|
Colorectal Neoplasms | 53 | 2023 | 6773 | 3.900 |
Why?
|
Hospice Care | 20 | 2022 | 672 | 3.430 |
Why?
|
Neoplasms | 69 | 2023 | 21683 | 3.420 |
Why?
|
Medical Oncology | 29 | 2023 | 2265 | 3.360 |
Why?
|
Lung Neoplasms | 56 | 2023 | 13102 | 3.190 |
Why?
|
Androgen Antagonists | 23 | 2022 | 1377 | 2.880 |
Why?
|
Terminal Care | 20 | 2021 | 1694 | 2.860 |
Why?
|
SEER Program | 41 | 2022 | 1508 | 2.820 |
Why?
|
Mammography | 19 | 2022 | 2476 | 2.680 |
Why?
|
Fee-for-Service Plans | 16 | 2023 | 694 | 2.590 |
Why?
|
Prostatic Neoplasms | 46 | 2022 | 11124 | 2.590 |
Why?
|
United States | 181 | 2024 | 69872 | 2.570 |
Why?
|
Patient Preference | 10 | 2022 | 890 | 2.540 |
Why?
|
Quality of Health Care | 29 | 2022 | 4371 | 2.380 |
Why?
|
Gonadotropin-Releasing Hormone | 17 | 2017 | 1205 | 2.280 |
Why?
|
United States Department of Veterans Affairs | 10 | 2015 | 875 | 2.180 |
Why?
|
Insurance Coverage | 21 | 2022 | 1901 | 2.120 |
Why?
|
Hospitals, Veterans | 8 | 2015 | 404 | 2.090 |
Why?
|
Antineoplastic Agents | 30 | 2023 | 13695 | 2.070 |
Why?
|
Prescription Fees | 4 | 2020 | 146 | 1.990 |
Why?
|
Patient Participation | 14 | 2020 | 1457 | 1.930 |
Why?
|
Aged | 206 | 2024 | 163280 | 1.900 |
Why?
|
Cost Sharing | 8 | 2023 | 407 | 1.860 |
Why?
|
Physicians, Primary Care | 8 | 2021 | 591 | 1.860 |
Why?
|
Decision Making | 24 | 2020 | 3887 | 1.840 |
Why?
|
Antineoplastic Agents, Hormonal | 13 | 2017 | 1524 | 1.810 |
Why?
|
Hospices | 11 | 2022 | 265 | 1.750 |
Why?
|
Proxy | 5 | 2020 | 144 | 1.720 |
Why?
|
Physician-Patient Relations | 23 | 2023 | 3229 | 1.670 |
Why?
|
Orchiectomy | 9 | 2014 | 474 | 1.660 |
Why?
|
Terminally Ill | 6 | 2016 | 238 | 1.660 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 5 | 2022 | 689 | 1.650 |
Why?
|
Physicians | 25 | 2024 | 4567 | 1.640 |
Why?
|
Quality Indicators, Health Care | 13 | 2021 | 1831 | 1.580 |
Why?
|
Early Detection of Cancer | 18 | 2023 | 3086 | 1.520 |
Why?
|
Prescription Drugs | 8 | 2023 | 595 | 1.450 |
Why?
|
Aged, 80 and over | 107 | 2022 | 57776 | 1.450 |
Why?
|
Humans | 350 | 2024 | 744343 | 1.420 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 12 | 2023 | 5221 | 1.420 |
Why?
|
Insurance, Health | 14 | 2022 | 2494 | 1.410 |
Why?
|
Specialization | 9 | 2023 | 777 | 1.360 |
Why?
|
Female | 219 | 2024 | 380194 | 1.320 |
Why?
|
Neoplasm Staging | 38 | 2021 | 11031 | 1.300 |
Why?
|
Referral and Consultation | 20 | 2021 | 3528 | 1.290 |
Why?
|
Healthcare Disparities | 13 | 2022 | 3158 | 1.280 |
Why?
|
Reimbursement Mechanisms | 4 | 2023 | 670 | 1.250 |
Why?
|
Contraceptive Agents, Female | 3 | 2019 | 135 | 1.220 |
Why?
|
Insurance, Pharmaceutical Services | 7 | 2021 | 336 | 1.220 |
Why?
|
Choice Behavior | 7 | 2016 | 803 | 1.200 |
Why?
|
Drug Costs | 11 | 2023 | 1105 | 1.190 |
Why?
|
Patient Protection and Affordable Care Act | 8 | 2021 | 1209 | 1.160 |
Why?
|
Survivors | 15 | 2023 | 2291 | 1.150 |
Why?
|
Middle Aged | 147 | 2023 | 213383 | 1.130 |
Why?
|
Male | 172 | 2024 | 350118 | 1.090 |
Why?
|
Insurance, Health, Reimbursement | 4 | 2015 | 397 | 1.060 |
Why?
|
Chemotherapy, Adjuvant | 16 | 2021 | 3479 | 1.060 |
Why?
|
Neoplasms, Hormone-Dependent | 4 | 2014 | 415 | 1.010 |
Why?
|
Medicaid | 10 | 2022 | 2736 | 1.000 |
Why?
|
Health Knowledge, Attitudes, Practice | 9 | 2018 | 3923 | 1.000 |
Why?
|
Cancer Care Facilities | 5 | 2021 | 402 | 0.960 |
Why?
|
Insurance Benefits | 3 | 2019 | 183 | 0.950 |
Why?
|
Interdisciplinary Communication | 5 | 2015 | 950 | 0.940 |
Why?
|
Health Care Surveys | 16 | 2023 | 2453 | 0.930 |
Why?
|
Insurance Claim Review | 8 | 2022 | 720 | 0.910 |
Why?
|
Health Care Costs | 10 | 2023 | 3209 | 0.910 |
Why?
|
Peer Group | 2 | 2019 | 635 | 0.910 |
Why?
|
Drugs, Generic | 7 | 2023 | 421 | 0.900 |
Why?
|
Logistic Models | 34 | 2020 | 13408 | 0.890 |
Why?
|
Primary Health Care | 14 | 2021 | 4558 | 0.880 |
Why?
|
Attitude of Health Personnel | 11 | 2021 | 3843 | 0.870 |
Why?
|
Medication Adherence | 9 | 2023 | 2063 | 0.860 |
Why?
|
Patient Satisfaction | 13 | 2018 | 3396 | 0.850 |
Why?
|
Mastectomy, Segmental | 7 | 2022 | 956 | 0.850 |
Why?
|
Prostatectomy | 10 | 2022 | 1890 | 0.850 |
Why?
|
Pharmacies | 1 | 2024 | 150 | 0.830 |
Why?
|
Intrauterine Devices | 3 | 2019 | 122 | 0.830 |
Why?
|
Veterans | 8 | 2022 | 2519 | 0.810 |
Why?
|
Cohort Studies | 52 | 2023 | 40561 | 0.790 |
Why?
|
Diabetes Mellitus | 13 | 2019 | 5751 | 0.780 |
Why?
|
Health Services Accessibility | 12 | 2023 | 5137 | 0.770 |
Why?
|
Health Status Disparities | 3 | 2022 | 1797 | 0.750 |
Why?
|
Hospitals | 7 | 2016 | 3952 | 0.720 |
Why?
|
Formularies as Topic | 3 | 2019 | 91 | 0.700 |
Why?
|
Family | 6 | 2017 | 3147 | 0.700 |
Why?
|
Communication | 12 | 2022 | 3749 | 0.700 |
Why?
|
Drug Prescriptions | 8 | 2022 | 1637 | 0.690 |
Why?
|
Patient Care Team | 5 | 2015 | 2531 | 0.690 |
Why?
|
Adult | 95 | 2023 | 214055 | 0.680 |
Why?
|
Managed Care Programs | 4 | 2006 | 950 | 0.670 |
Why?
|
Prescriptions | 3 | 2023 | 387 | 0.670 |
Why?
|
Legislation, Medical | 1 | 2019 | 100 | 0.670 |
Why?
|
Continuity of Patient Care | 6 | 2022 | 1049 | 0.660 |
Why?
|
Home Care Services | 4 | 2013 | 606 | 0.650 |
Why?
|
Medicare Part C | 1 | 2023 | 296 | 0.650 |
Why?
|
Income | 5 | 2021 | 1913 | 0.650 |
Why?
|
Geography | 2 | 2018 | 669 | 0.640 |
Why?
|
Neoplasms, Glandular and Epithelial | 3 | 2018 | 484 | 0.640 |
Why?
|
Ovarian Neoplasms | 8 | 2022 | 4838 | 0.640 |
Why?
|
Delivery of Health Care | 10 | 2023 | 5319 | 0.630 |
Why?
|
Medically Uninsured | 4 | 2020 | 853 | 0.630 |
Why?
|
Breast | 5 | 2023 | 1969 | 0.620 |
Why?
|
Administration, Oral | 8 | 2020 | 3913 | 0.620 |
Why?
|
Life Expectancy | 7 | 2022 | 1184 | 0.610 |
Why?
|
Ambulatory Care | 5 | 2015 | 2708 | 0.590 |
Why?
|
Mastectomy | 8 | 2016 | 1793 | 0.590 |
Why?
|
Contraception Behavior | 1 | 2019 | 185 | 0.580 |
Why?
|
Mouth Neoplasms | 1 | 2022 | 601 | 0.570 |
Why?
|
Minority Health | 2 | 2015 | 87 | 0.570 |
Why?
|
Mass Screening | 11 | 2023 | 5255 | 0.570 |
Why?
|
Aromatase Inhibitors | 4 | 2013 | 491 | 0.570 |
Why?
|
Patient Care Planning | 2 | 2020 | 921 | 0.560 |
Why?
|
Health Services Research | 9 | 2019 | 1836 | 0.550 |
Why?
|
Interprofessional Relations | 7 | 2017 | 1011 | 0.550 |
Why?
|
Odds Ratio | 13 | 2020 | 9849 | 0.550 |
Why?
|
Peer Review, Research | 1 | 2019 | 329 | 0.540 |
Why?
|
Cross-Sectional Studies | 26 | 2024 | 25043 | 0.540 |
Why?
|
Kidney Failure, Chronic | 5 | 2022 | 2538 | 0.530 |
Why?
|
Government Regulation | 2 | 2019 | 522 | 0.530 |
Why?
|
Propensity Score | 9 | 2018 | 1781 | 0.530 |
Why?
|
Combined Modality Therapy | 6 | 2019 | 8642 | 0.530 |
Why?
|
California | 8 | 2017 | 1402 | 0.530 |
Why?
|
Emigrants and Immigrants | 3 | 2013 | 522 | 0.530 |
Why?
|
Employment | 4 | 2010 | 1132 | 0.520 |
Why?
|
Socioeconomic Factors | 15 | 2018 | 7785 | 0.520 |
Why?
|
Communicable Diseases | 1 | 2024 | 880 | 0.520 |
Why?
|
Patient Care | 4 | 2019 | 640 | 0.510 |
Why?
|
Leukemia | 1 | 2023 | 1511 | 0.510 |
Why?
|
Reimbursement, Incentive | 3 | 2014 | 540 | 0.510 |
Why?
|
False Positive Reactions | 4 | 2019 | 981 | 0.500 |
Why?
|
Diabetes Complications | 3 | 2018 | 1359 | 0.500 |
Why?
|
Proportional Hazards Models | 17 | 2022 | 12354 | 0.500 |
Why?
|
Health Literacy | 2 | 2023 | 414 | 0.500 |
Why?
|
Nursing Homes | 4 | 2010 | 1036 | 0.490 |
Why?
|
Preferred Provider Organizations | 2 | 2019 | 38 | 0.490 |
Why?
|
Research Personnel | 2 | 2019 | 573 | 0.480 |
Why?
|
Angiogenesis Inhibitors | 2 | 2015 | 2038 | 0.480 |
Why?
|
Practice Guidelines as Topic | 13 | 2018 | 7279 | 0.470 |
Why?
|
Age Factors | 22 | 2018 | 18370 | 0.470 |
Why?
|
Medicare Part B | 2 | 2022 | 108 | 0.470 |
Why?
|
Neoadjuvant Therapy | 5 | 2021 | 2728 | 0.470 |
Why?
|
Benzamides | 2 | 2022 | 1379 | 0.460 |
Why?
|
Calcifediol | 1 | 2014 | 166 | 0.450 |
Why?
|
Disclosure | 1 | 2019 | 736 | 0.450 |
Why?
|
Cardiovascular Diseases | 14 | 2017 | 15165 | 0.450 |
Why?
|
Colonic Neoplasms | 4 | 2015 | 2541 | 0.440 |
Why?
|
Contraception | 1 | 2016 | 359 | 0.440 |
Why?
|
Health Services Misuse | 1 | 2014 | 243 | 0.430 |
Why?
|
Bile Duct Diseases | 1 | 2013 | 100 | 0.430 |
Why?
|
Radiotherapy, Adjuvant | 10 | 2016 | 1770 | 0.430 |
Why?
|
Politics | 1 | 2019 | 791 | 0.420 |
Why?
|
Caregivers | 4 | 2022 | 2094 | 0.420 |
Why?
|
Practice Management, Medical | 3 | 2019 | 196 | 0.420 |
Why?
|
Catastrophization | 1 | 2015 | 316 | 0.400 |
Why?
|
Pulmonary Surgical Procedures | 1 | 2011 | 29 | 0.400 |
Why?
|
Patient Acceptance of Health Care | 4 | 2018 | 3022 | 0.400 |
Why?
|
Physician Incentive Plans | 1 | 2012 | 161 | 0.390 |
Why?
|
Ownership | 2 | 2016 | 332 | 0.390 |
Why?
|
Multivariate Analysis | 15 | 2017 | 12245 | 0.390 |
Why?
|
Guideline Adherence | 8 | 2015 | 2266 | 0.390 |
Why?
|
Trust | 2 | 2007 | 505 | 0.390 |
Why?
|
Health Facility Size | 2 | 2012 | 64 | 0.380 |
Why?
|
Tamoxifen | 2 | 2012 | 981 | 0.380 |
Why?
|
Neoplasm Metastasis | 11 | 2018 | 4851 | 0.380 |
Why?
|
Data Collection | 10 | 2015 | 3341 | 0.380 |
Why?
|
Medical Records | 2 | 2015 | 1413 | 0.380 |
Why?
|
Colonoscopy | 3 | 2018 | 1367 | 0.380 |
Why?
|
BRCA2 Protein | 2 | 2022 | 794 | 0.380 |
Why?
|
Aftercare | 1 | 2017 | 866 | 0.370 |
Why?
|
Thiazides | 1 | 2010 | 18 | 0.370 |
Why?
|
Truth Disclosure | 2 | 2014 | 436 | 0.370 |
Why?
|
Motivation | 1 | 2020 | 1971 | 0.370 |
Why?
|
Radiotherapy | 3 | 2015 | 1533 | 0.370 |
Why?
|
Rwanda | 7 | 2023 | 703 | 0.370 |
Why?
|
Diphenhydramine | 1 | 2010 | 63 | 0.370 |
Why?
|
Small Cell Lung Carcinoma | 1 | 2015 | 388 | 0.370 |
Why?
|
Hospital Costs | 3 | 2018 | 985 | 0.360 |
Why?
|
Sodium Chloride Symporter Inhibitors | 1 | 2010 | 76 | 0.360 |
Why?
|
Bone Density | 3 | 2012 | 3468 | 0.360 |
Why?
|
Quality of Life | 10 | 2022 | 12804 | 0.360 |
Why?
|
Medicine | 5 | 2011 | 946 | 0.350 |
Why?
|
Uterine Cervical Neoplasms | 3 | 2023 | 2020 | 0.350 |
Why?
|
Health Status | 6 | 2020 | 4034 | 0.350 |
Why?
|
Palliative Care | 8 | 2019 | 3493 | 0.350 |
Why?
|
Myocardial Infarction | 8 | 2014 | 11727 | 0.350 |
Why?
|
Time Factors | 20 | 2021 | 40075 | 0.350 |
Why?
|
Bone Neoplasms | 1 | 2022 | 2529 | 0.350 |
Why?
|
Models, Theoretical | 2 | 2019 | 3589 | 0.340 |
Why?
|
Risk Factors | 27 | 2021 | 72290 | 0.340 |
Why?
|
Social Support | 2 | 2011 | 2118 | 0.340 |
Why?
|
Cost of Illness | 3 | 2022 | 1859 | 0.340 |
Why?
|
Protein-Tyrosine Kinases | 3 | 2017 | 2455 | 0.340 |
Why?
|
Length of Stay | 5 | 2018 | 6309 | 0.340 |
Why?
|
Delivery of Health Care, Integrated | 4 | 2023 | 941 | 0.330 |
Why?
|
BRCA1 Protein | 2 | 2022 | 1149 | 0.330 |
Why?
|
Patient Selection | 4 | 2014 | 4215 | 0.330 |
Why?
|
Comorbidity | 11 | 2015 | 10388 | 0.330 |
Why?
|
Ibuprofen | 1 | 2010 | 236 | 0.330 |
Why?
|
Registries | 10 | 2022 | 8089 | 0.330 |
Why?
|
Young Adult | 24 | 2019 | 56430 | 0.320 |
Why?
|
Ultraviolet Rays | 1 | 2013 | 1060 | 0.320 |
Why?
|
Prospective Studies | 21 | 2021 | 53288 | 0.320 |
Why?
|
Health Education | 1 | 2015 | 1056 | 0.310 |
Why?
|
Retrospective Studies | 36 | 2023 | 77449 | 0.310 |
Why?
|
Health Facilities | 3 | 2019 | 573 | 0.300 |
Why?
|
Commerce | 3 | 2023 | 592 | 0.300 |
Why?
|
Risk | 6 | 2019 | 9687 | 0.300 |
Why?
|
Ultrasonography, Mammary | 2 | 2019 | 250 | 0.290 |
Why?
|
Comprehension | 3 | 2019 | 610 | 0.290 |
Why?
|
National Cancer Institute (U.S.) | 3 | 2023 | 288 | 0.290 |
Why?
|
Patient Transfer | 2 | 2011 | 761 | 0.290 |
Why?
|
Pneumonectomy | 2 | 2011 | 1094 | 0.280 |
Why?
|
Maryland | 3 | 2023 | 276 | 0.280 |
Why?
|
Survival Rate | 13 | 2019 | 12788 | 0.280 |
Why?
|
Insurance Carriers | 2 | 2018 | 157 | 0.280 |
Why?
|
Prognosis | 12 | 2023 | 29063 | 0.270 |
Why?
|
Patient-Centered Care | 2 | 2017 | 1439 | 0.270 |
Why?
|
Treatment Outcome | 21 | 2022 | 63114 | 0.270 |
Why?
|
Minnesota | 5 | 2004 | 344 | 0.270 |
Why?
|
Cost Savings | 2 | 2021 | 926 | 0.270 |
Why?
|
Health Personnel | 3 | 2019 | 3218 | 0.260 |
Why?
|
Mammaplasty | 1 | 2015 | 1204 | 0.260 |
Why?
|
Insulin | 1 | 2020 | 6580 | 0.260 |
Why?
|
Health Care Reform | 3 | 2020 | 1261 | 0.260 |
Why?
|
Radiation Oncology | 3 | 2015 | 555 | 0.260 |
Why?
|
Health Promotion | 2 | 2014 | 2205 | 0.260 |
Why?
|
Costs and Cost Analysis | 4 | 2022 | 1681 | 0.250 |
Why?
|
Quality Improvement | 2 | 2019 | 3749 | 0.250 |
Why?
|
Community Networks | 3 | 2018 | 203 | 0.250 |
Why?
|
Interviews as Topic | 5 | 2019 | 2539 | 0.250 |
Why?
|
Hospitalization | 9 | 2021 | 10262 | 0.250 |
Why?
|
Military Personnel | 1 | 2013 | 1133 | 0.250 |
Why?
|
Population Surveillance | 5 | 2017 | 2616 | 0.250 |
Why?
|
Residence Characteristics | 5 | 2016 | 2050 | 0.250 |
Why?
|
Cost Control | 3 | 2019 | 624 | 0.250 |
Why?
|
Receptor, erbB-2 | 4 | 2016 | 2416 | 0.250 |
Why?
|
Vitamin D Deficiency | 1 | 2014 | 1343 | 0.240 |
Why?
|
Community Health Services | 2 | 2009 | 650 | 0.240 |
Why?
|
Incidence | 11 | 2016 | 20947 | 0.240 |
Why?
|
Activities of Daily Living | 3 | 2008 | 2418 | 0.230 |
Why?
|
Workload | 1 | 2009 | 850 | 0.230 |
Why?
|
Genetic Testing | 3 | 2022 | 3444 | 0.230 |
Why?
|
Triazoles | 1 | 2009 | 911 | 0.230 |
Why?
|
Health Benefit Plans, Employee | 2 | 2018 | 332 | 0.230 |
Why?
|
Fees, Pharmaceutical | 2 | 2020 | 64 | 0.230 |
Why?
|
Eligibility Determination | 1 | 2007 | 403 | 0.230 |
Why?
|
Unnecessary Procedures | 1 | 2007 | 432 | 0.220 |
Why?
|
Smoking | 5 | 2014 | 8987 | 0.220 |
Why?
|
Piperazines | 1 | 2013 | 2488 | 0.220 |
Why?
|
Evidence-Based Medicine | 6 | 2014 | 3610 | 0.220 |
Why?
|
Goals | 3 | 2023 | 706 | 0.220 |
Why?
|
Pyrazines | 1 | 2009 | 1230 | 0.220 |
Why?
|
Multiple Myeloma | 2 | 2020 | 5181 | 0.220 |
Why?
|
Protein Kinase Inhibitors | 3 | 2020 | 5535 | 0.220 |
Why?
|
Diabetes Mellitus, Type 2 | 5 | 2012 | 11725 | 0.220 |
Why?
|
Minority Groups | 3 | 2016 | 1223 | 0.220 |
Why?
|
Sensitivity and Specificity | 6 | 2019 | 14722 | 0.220 |
Why?
|
United States Food and Drug Administration | 3 | 2019 | 1584 | 0.220 |
Why?
|
Medicare Part A | 1 | 2022 | 39 | 0.220 |
Why?
|
Health Behavior | 3 | 2011 | 2636 | 0.210 |
Why?
|
Severity of Illness Index | 5 | 2017 | 15540 | 0.210 |
Why?
|
Emetics | 1 | 2022 | 9 | 0.210 |
Why?
|
Drug Utilization | 3 | 2021 | 1183 | 0.210 |
Why?
|
Periodicals as Topic | 2 | 2023 | 1432 | 0.210 |
Why?
|
Survival Analysis | 8 | 2018 | 10252 | 0.210 |
Why?
|
Rosa | 1 | 2021 | 8 | 0.210 |
Why?
|
Therapies, Investigational | 1 | 2023 | 112 | 0.210 |
Why?
|
Metformin | 1 | 2009 | 835 | 0.210 |
Why?
|
Diabetic Angiopathies | 1 | 2007 | 818 | 0.210 |
Why?
|
Sunlight | 2 | 2014 | 325 | 0.200 |
Why?
|
Neoplasm Recurrence, Local | 6 | 2022 | 9239 | 0.200 |
Why?
|
Chi-Square Distribution | 6 | 2018 | 3508 | 0.200 |
Why?
|
Pyrimidines | 1 | 2013 | 2942 | 0.200 |
Why?
|
Longevity | 2 | 2015 | 1070 | 0.200 |
Why?
|
Regression Analysis | 6 | 2017 | 6459 | 0.200 |
Why?
|
Androstenes | 1 | 2022 | 170 | 0.200 |
Why?
|
Longitudinal Studies | 6 | 2018 | 13989 | 0.190 |
Why?
|
Family Practice | 1 | 2004 | 516 | 0.190 |
Why?
|
Perception | 2 | 2020 | 1198 | 0.190 |
Why?
|
Long-Term Care | 2 | 2020 | 607 | 0.190 |
Why?
|
Drug Therapy | 2 | 2015 | 497 | 0.190 |
Why?
|
Psychotropic Drugs | 1 | 2007 | 894 | 0.190 |
Why?
|
Diagnostic Tests, Routine | 1 | 2007 | 783 | 0.190 |
Why?
|
Hypoglycemic Agents | 3 | 2019 | 2872 | 0.190 |
Why?
|
Phenylthiohydantoin | 1 | 2022 | 193 | 0.190 |
Why?
|
Episode of Care | 1 | 2021 | 126 | 0.190 |
Why?
|
Peripheral Arterial Disease | 1 | 2012 | 1188 | 0.190 |
Why?
|
Stroke | 4 | 2014 | 9981 | 0.190 |
Why?
|
Genomics | 1 | 2017 | 5720 | 0.190 |
Why?
|
Turner Syndrome | 1 | 2022 | 130 | 0.190 |
Why?
|
Advance Directives | 2 | 2020 | 246 | 0.190 |
Why?
|
Deductibles and Coinsurance | 2 | 2021 | 316 | 0.190 |
Why?
|
Budgets | 1 | 2022 | 229 | 0.190 |
Why?
|
Antidepressive Agents | 1 | 2012 | 2838 | 0.190 |
Why?
|
Biopsy | 4 | 2019 | 6756 | 0.180 |
Why?
|
Diagnostic Imaging | 1 | 2014 | 3507 | 0.180 |
Why?
|
Postal Service | 1 | 2020 | 96 | 0.180 |
Why?
|
General Surgery | 3 | 2023 | 1636 | 0.180 |
Why?
|
Fractures, Bone | 2 | 2011 | 1947 | 0.180 |
Why?
|
Fasting | 1 | 2006 | 1593 | 0.180 |
Why?
|
Philadelphia | 1 | 2020 | 266 | 0.180 |
Why?
|
Massachusetts | 5 | 2022 | 8663 | 0.180 |
Why?
|
Intensive Care Units | 5 | 2020 | 3679 | 0.180 |
Why?
|
Internal Medicine | 2 | 2013 | 1009 | 0.180 |
Why?
|
Salvage Therapy | 2 | 2016 | 1275 | 0.180 |
Why?
|
Nitriles | 2 | 2022 | 956 | 0.170 |
Why?
|
Vitamin D | 1 | 2013 | 3223 | 0.170 |
Why?
|
Teaching | 2 | 2019 | 1174 | 0.170 |
Why?
|
Venous Thromboembolism | 1 | 2012 | 1671 | 0.170 |
Why?
|
Testosterone | 1 | 2009 | 2420 | 0.170 |
Why?
|
For-Profit Insurance Plans | 1 | 2018 | 8 | 0.170 |
Why?
|
Sick Leave | 1 | 1999 | 110 | 0.170 |
Why?
|
Research Design | 5 | 2012 | 5987 | 0.160 |
Why?
|
Blood Glucose | 3 | 2010 | 6256 | 0.160 |
Why?
|
Negotiating | 2 | 2023 | 133 | 0.160 |
Why?
|
Information Dissemination | 1 | 2007 | 1099 | 0.160 |
Why?
|
Health Services for the Aged | 1 | 2021 | 269 | 0.160 |
Why?
|
Models, Economic | 2 | 2019 | 713 | 0.160 |
Why?
|
Disease-Free Survival | 3 | 2018 | 6895 | 0.160 |
Why?
|
Follow-Up Studies | 9 | 2022 | 39050 | 0.160 |
Why?
|
Drug Implants | 1 | 2019 | 244 | 0.160 |
Why?
|
Clinical Trials as Topic | 5 | 2019 | 7913 | 0.160 |
Why?
|
Professional Practice | 3 | 2012 | 326 | 0.160 |
Why?
|
Residential Facilities | 1 | 2018 | 43 | 0.160 |
Why?
|
Reproductive Techniques, Assisted | 1 | 2022 | 482 | 0.150 |
Why?
|
Cooperative Behavior | 3 | 2015 | 1504 | 0.150 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 2 | 2010 | 3047 | 0.150 |
Why?
|
Role | 3 | 2010 | 175 | 0.150 |
Why?
|
Health Policy | 3 | 2019 | 2661 | 0.150 |
Why?
|
Africa South of the Sahara | 1 | 2020 | 724 | 0.150 |
Why?
|
Tennessee | 1 | 2017 | 117 | 0.150 |
Why?
|
Women's Health | 1 | 2007 | 2034 | 0.150 |
Why?
|
Personnel, Hospital | 1 | 1999 | 283 | 0.150 |
Why?
|
Death, Sudden, Cardiac | 3 | 2012 | 1541 | 0.150 |
Why?
|
Patients | 4 | 2017 | 900 | 0.150 |
Why?
|
Adolescent | 11 | 2019 | 85781 | 0.150 |
Why?
|
Liver Neoplasms | 1 | 2013 | 4253 | 0.150 |
Why?
|
Clinical Competence | 4 | 2018 | 4687 | 0.150 |
Why?
|
Quality Assurance, Health Care | 1 | 2007 | 2212 | 0.150 |
Why?
|
Private Sector | 2 | 2011 | 392 | 0.150 |
Why?
|
Area Under Curve | 2 | 2019 | 1654 | 0.140 |
Why?
|
Death | 5 | 2023 | 678 | 0.140 |
Why?
|
Risk Assessment | 11 | 2016 | 23338 | 0.140 |
Why?
|
Patient Education as Topic | 4 | 2014 | 2278 | 0.140 |
Why?
|
Job Satisfaction | 2 | 2014 | 535 | 0.140 |
Why?
|
Delayed Diagnosis | 2 | 2022 | 441 | 0.140 |
Why?
|
Mental Health | 4 | 2018 | 3019 | 0.140 |
Why?
|
Infusions, Intravenous | 2 | 2018 | 2274 | 0.140 |
Why?
|
Hysterectomy | 2 | 2018 | 927 | 0.140 |
Why?
|
Analgesics, Opioid | 2 | 2023 | 3674 | 0.130 |
Why?
|
Kaplan-Meier Estimate | 5 | 2018 | 6538 | 0.130 |
Why?
|
Attitude to Health | 2 | 2017 | 2052 | 0.130 |
Why?
|
Subacute Care | 1 | 2018 | 168 | 0.130 |
Why?
|
Family Health | 1 | 2020 | 1282 | 0.130 |
Why?
|
Intestinal Perforation | 1 | 2017 | 253 | 0.130 |
Why?
|
Contract Services | 1 | 2015 | 94 | 0.130 |
Why?
|
Aspirin | 1 | 2007 | 3282 | 0.130 |
Why?
|
Goserelin | 2 | 2017 | 129 | 0.130 |
Why?
|
Prostate-Specific Antigen | 5 | 2018 | 2494 | 0.130 |
Why?
|
Colitis, Ulcerative | 1 | 2007 | 1912 | 0.130 |
Why?
|
Postmenopause | 3 | 2013 | 2461 | 0.130 |
Why?
|
Adenocarcinoma, Clear Cell | 1 | 2016 | 221 | 0.130 |
Why?
|
Educational Status | 2 | 2013 | 2540 | 0.120 |
Why?
|
Databases, Factual | 4 | 2018 | 7729 | 0.120 |
Why?
|
Platelet Aggregation Inhibitors | 1 | 2007 | 3068 | 0.120 |
Why?
|
Iowa | 1 | 2014 | 101 | 0.120 |
Why?
|
Sleep | 1 | 2010 | 4623 | 0.120 |
Why?
|
Alabama | 1 | 2014 | 98 | 0.120 |
Why?
|
Research | 2 | 2022 | 1999 | 0.120 |
Why?
|
Withholding Treatment | 2 | 2016 | 599 | 0.120 |
Why?
|
Culture | 1 | 2018 | 633 | 0.120 |
Why?
|
Neoplasms, Cystic, Mucinous, and Serous | 1 | 2016 | 198 | 0.120 |
Why?
|
Fees and Charges | 1 | 2015 | 195 | 0.120 |
Why?
|
Needs Assessment | 2 | 2017 | 1147 | 0.120 |
Why?
|
Leuprolide | 2 | 2017 | 321 | 0.120 |
Why?
|
Carcinoma, Endometrioid | 1 | 2016 | 271 | 0.120 |
Why?
|
Algorithms | 4 | 2021 | 13881 | 0.120 |
Why?
|
Hospitals, Rural | 1 | 2015 | 172 | 0.110 |
Why?
|
North Carolina | 1 | 2014 | 315 | 0.110 |
Why?
|
Cost-Benefit Analysis | 4 | 2016 | 5391 | 0.110 |
Why?
|
Hormone Replacement Therapy | 1 | 1999 | 745 | 0.110 |
Why?
|
Heart Diseases | 1 | 2006 | 2788 | 0.110 |
Why?
|
Lymph Node Excision | 3 | 2016 | 1261 | 0.110 |
Why?
|
Information Seeking Behavior | 1 | 2014 | 113 | 0.110 |
Why?
|
Genital Neoplasms, Female | 1 | 2018 | 523 | 0.110 |
Why?
|
Physician's Role | 2 | 2011 | 943 | 0.110 |
Why?
|
Poverty | 2 | 2022 | 2660 | 0.110 |
Why?
|
Thalidomide | 1 | 2018 | 890 | 0.110 |
Why?
|
Life Tables | 1 | 2013 | 370 | 0.110 |
Why?
|
Veterans Health | 1 | 2014 | 216 | 0.110 |
Why?
|
Risk Reduction Behavior | 1 | 2019 | 1125 | 0.110 |
Why?
|
Seasons | 2 | 2014 | 1493 | 0.110 |
Why?
|
Ultrasonography | 2 | 2016 | 5985 | 0.110 |
Why?
|
Endpoint Determination | 1 | 2015 | 601 | 0.110 |
Why?
|
Drug Industry | 2 | 2019 | 746 | 0.110 |
Why?
|
Mexico | 1 | 2014 | 690 | 0.110 |
Why?
|
Professional-Family Relations | 1 | 2016 | 482 | 0.100 |
Why?
|
Confidence Intervals | 2 | 2012 | 2971 | 0.100 |
Why?
|
Hospital-Physician Joint Ventures | 1 | 2012 | 30 | 0.100 |
Why?
|
Health Services | 1 | 2017 | 758 | 0.100 |
Why?
|
Gastrointestinal Hemorrhage | 2 | 2017 | 1130 | 0.100 |
Why?
|
Awareness | 2 | 2014 | 640 | 0.100 |
Why?
|
Factor Analysis, Statistical | 1 | 2015 | 977 | 0.100 |
Why?
|
Review Literature as Topic | 1 | 2014 | 336 | 0.100 |
Why?
|
Carcinoma, Lobular | 1 | 2016 | 484 | 0.100 |
Why?
|
Reproducibility of Results | 2 | 2021 | 19905 | 0.100 |
Why?
|
Natural Language Processing | 1 | 2020 | 1041 | 0.100 |
Why?
|
Pilot Projects | 2 | 2022 | 8324 | 0.100 |
Why?
|
Behavioral Risk Factor Surveillance System | 1 | 2012 | 199 | 0.100 |
Why?
|
Statistics, Nonparametric | 3 | 2004 | 2886 | 0.100 |
Why?
|
Medical Record Linkage | 1 | 2012 | 284 | 0.100 |
Why?
|
Geriatric Assessment | 2 | 2021 | 1372 | 0.100 |
Why?
|
Academic Medical Centers | 3 | 2013 | 2759 | 0.100 |
Why?
|
Immunologic Factors | 1 | 2020 | 1580 | 0.100 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2016 | 602 | 0.100 |
Why?
|
Orthopedics | 1 | 2000 | 904 | 0.100 |
Why?
|
Organizational Affiliation | 1 | 2010 | 33 | 0.090 |
Why?
|
Pain | 2 | 2017 | 4986 | 0.090 |
Why?
|
Patient Readmission | 2 | 2022 | 3114 | 0.090 |
Why?
|
Drug Labeling | 1 | 2012 | 233 | 0.090 |
Why?
|
Preoperative Care | 1 | 2019 | 2250 | 0.090 |
Why?
|
Receptors, Progesterone | 1 | 2015 | 1097 | 0.090 |
Why?
|
Advance Care Planning | 1 | 2017 | 662 | 0.090 |
Why?
|
Disease Outbreaks | 1 | 1999 | 1772 | 0.090 |
Why?
|
Hypertension | 1 | 2010 | 8480 | 0.090 |
Why?
|
Attitude to Death | 1 | 2012 | 382 | 0.090 |
Why?
|
Friends | 1 | 2011 | 154 | 0.090 |
Why?
|
Pregnancy | 3 | 2022 | 29144 | 0.090 |
Why?
|
Patient Compliance | 2 | 2018 | 2684 | 0.090 |
Why?
|
Cause of Death | 2 | 2018 | 3584 | 0.090 |
Why?
|
North America | 2 | 2015 | 1249 | 0.090 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 3 | 2015 | 11524 | 0.090 |
Why?
|
Linear Models | 4 | 2018 | 5952 | 0.090 |
Why?
|
Photons | 1 | 2013 | 588 | 0.080 |
Why?
|
Neoplasms, Radiation-Induced | 1 | 2013 | 547 | 0.080 |
Why?
|
Mortality | 1 | 2020 | 2864 | 0.080 |
Why?
|
Meta-Analysis as Topic | 1 | 2014 | 1344 | 0.080 |
Why?
|
Social Perception | 1 | 2012 | 425 | 0.080 |
Why?
|
Transurethral Resection of Prostate | 1 | 2009 | 83 | 0.080 |
Why?
|
Cardiology | 1 | 2000 | 1668 | 0.080 |
Why?
|
Aging | 1 | 2008 | 8664 | 0.080 |
Why?
|
Age of Onset | 2 | 2015 | 3271 | 0.080 |
Why?
|
Drug Approval | 1 | 2015 | 742 | 0.080 |
Why?
|
Organizations, Nonprofit | 1 | 2009 | 104 | 0.080 |
Why?
|
Carcinoma, Ductal, Breast | 1 | 2016 | 1101 | 0.080 |
Why?
|
Rural Population | 2 | 2017 | 2210 | 0.080 |
Why?
|
Influenza, Human | 1 | 1999 | 1479 | 0.080 |
Why?
|
Small-Area Analysis | 1 | 2008 | 55 | 0.080 |
Why?
|
Disease Management | 1 | 2019 | 2459 | 0.080 |
Why?
|
Laparoscopy | 2 | 2018 | 2151 | 0.080 |
Why?
|
Drug Interactions | 1 | 2012 | 1460 | 0.080 |
Why?
|
Medical Order Entry Systems | 1 | 2013 | 545 | 0.080 |
Why?
|
Emotions | 1 | 2019 | 2661 | 0.080 |
Why?
|
Estrogens | 1 | 2014 | 1566 | 0.080 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2015 | 9959 | 0.080 |
Why?
|
Health Surveys | 1 | 2018 | 4037 | 0.080 |
Why?
|
Smoking Cessation | 3 | 2019 | 2071 | 0.080 |
Why?
|
Public Sector | 1 | 2009 | 265 | 0.070 |
Why?
|
Arrhythmias, Cardiac | 1 | 2017 | 2268 | 0.070 |
Why?
|
New England | 1 | 2010 | 1022 | 0.070 |
Why?
|
Immunotherapy | 1 | 2023 | 4445 | 0.070 |
Why?
|
Physicians, Family | 1 | 2009 | 345 | 0.070 |
Why?
|
Postoperative Complications | 1 | 2009 | 15295 | 0.070 |
Why?
|
Geriatrics | 1 | 2012 | 396 | 0.070 |
Why?
|
International Cooperation | 1 | 2014 | 1420 | 0.070 |
Why?
|
Mental Disorders | 1 | 2007 | 6600 | 0.070 |
Why?
|
Institutionalization | 1 | 2007 | 104 | 0.070 |
Why?
|
Financing, Personal | 1 | 2009 | 308 | 0.070 |
Why?
|
Forecasting | 1 | 2016 | 2951 | 0.070 |
Why?
|
Patient Discharge | 2 | 2010 | 3313 | 0.070 |
Why?
|
Life Style | 1 | 2018 | 3835 | 0.070 |
Why?
|
Self Report | 2 | 2020 | 3558 | 0.070 |
Why?
|
Lymph Nodes | 2 | 2016 | 3474 | 0.070 |
Why?
|
Renal Dialysis | 3 | 2022 | 1786 | 0.070 |
Why?
|
Receptors, Estrogen | 1 | 2015 | 2187 | 0.070 |
Why?
|
Quality-Adjusted Life Years | 1 | 2013 | 1683 | 0.070 |
Why?
|
Personnel Staffing and Scheduling | 1 | 2010 | 501 | 0.070 |
Why?
|
Hormones | 1 | 2010 | 889 | 0.070 |
Why?
|
Marriage | 2 | 2010 | 339 | 0.070 |
Why?
|
Siblings | 1 | 2011 | 854 | 0.070 |
Why?
|
Blood Glucose Self-Monitoring | 1 | 2009 | 434 | 0.070 |
Why?
|
Specialties, Surgical | 1 | 2011 | 391 | 0.070 |
Why?
|
Uncertainty | 2 | 2022 | 734 | 0.070 |
Why?
|
Empathy | 1 | 2010 | 474 | 0.070 |
Why?
|
Erectile Dysfunction | 1 | 2009 | 461 | 0.070 |
Why?
|
Rectal Neoplasms | 2 | 2012 | 1206 | 0.070 |
Why?
|
Advisory Committees | 1 | 2010 | 775 | 0.070 |
Why?
|
Intercellular Signaling Peptides and Proteins | 1 | 2012 | 1676 | 0.060 |
Why?
|
Depression | 3 | 2014 | 7766 | 0.060 |
Why?
|
Neoplasms, Second Primary | 1 | 2013 | 1061 | 0.060 |
Why?
|
Urinary Incontinence | 1 | 2009 | 496 | 0.060 |
Why?
|
Patient Admission | 1 | 2012 | 1380 | 0.060 |
Why?
|
Pediatrics | 1 | 2000 | 3475 | 0.060 |
Why?
|
Drug Combinations | 1 | 2010 | 1959 | 0.060 |
Why?
|
Coronary Disease | 2 | 2012 | 6077 | 0.060 |
Why?
|
Genetic Counseling | 1 | 2008 | 600 | 0.060 |
Why?
|
Early Diagnosis | 1 | 2009 | 1184 | 0.060 |
Why?
|
Social Class | 2 | 2010 | 1999 | 0.060 |
Why?
|
Health Resources | 1 | 2010 | 911 | 0.060 |
Why?
|
Internet | 1 | 2016 | 3064 | 0.060 |
Why?
|
Sex Factors | 3 | 2015 | 10397 | 0.060 |
Why?
|
Cardiovascular Agents | 1 | 2010 | 850 | 0.060 |
Why?
|
Lung | 1 | 2022 | 9856 | 0.060 |
Why?
|
Urology | 1 | 2008 | 399 | 0.060 |
Why?
|
Thoracic Surgery | 1 | 2010 | 719 | 0.060 |
Why?
|
Case-Control Studies | 3 | 2018 | 21746 | 0.060 |
Why?
|
Demography | 2 | 2017 | 1656 | 0.060 |
Why?
|
Apoptosis Regulatory Proteins | 1 | 2008 | 1157 | 0.060 |
Why?
|
Anxiety | 2 | 2015 | 4297 | 0.060 |
Why?
|
Glucose Tolerance Test | 1 | 2006 | 1150 | 0.060 |
Why?
|
Government Programs | 1 | 2005 | 275 | 0.060 |
Why?
|
Health Care Sector | 1 | 2005 | 194 | 0.060 |
Why?
|
Emergency Service, Hospital | 4 | 2021 | 7659 | 0.060 |
Why?
|
Professional Autonomy | 1 | 2004 | 177 | 0.050 |
Why?
|
Efficiency, Organizational | 1 | 2007 | 695 | 0.050 |
Why?
|
Heart Failure | 2 | 2017 | 10900 | 0.050 |
Why?
|
Epidemiologic Methods | 1 | 2008 | 1364 | 0.050 |
Why?
|
Office Visits | 1 | 2007 | 598 | 0.050 |
Why?
|
Financial Management | 1 | 2004 | 160 | 0.050 |
Why?
|
Anemia | 1 | 2012 | 1506 | 0.050 |
Why?
|
Mental Health Services | 1 | 2013 | 1643 | 0.050 |
Why?
|
Exercise | 1 | 2018 | 5615 | 0.050 |
Why?
|
Hypnotics and Sedatives | 1 | 2010 | 1162 | 0.050 |
Why?
|
Health Status Indicators | 1 | 2007 | 969 | 0.050 |
Why?
|
District of Columbia | 1 | 2002 | 157 | 0.050 |
Why?
|
Prevalence | 5 | 2021 | 15226 | 0.050 |
Why?
|
Georgia | 1 | 2002 | 186 | 0.050 |
Why?
|
Women | 1 | 1983 | 230 | 0.050 |
Why?
|
Baltimore | 1 | 2002 | 231 | 0.050 |
Why?
|
Adult Children | 1 | 2022 | 100 | 0.050 |
Why?
|
Axilla | 1 | 2003 | 595 | 0.050 |
Why?
|
Telemedicine | 2 | 2018 | 2872 | 0.050 |
Why?
|
Age Distribution | 2 | 2018 | 2902 | 0.050 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2007 | 1518 | 0.050 |
Why?
|
Florida | 1 | 2002 | 435 | 0.050 |
Why?
|
Boston | 2 | 2011 | 9313 | 0.050 |
Why?
|
Benchmarking | 1 | 2007 | 1042 | 0.050 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2010 | 2282 | 0.050 |
Why?
|
Hematologic Neoplasms | 1 | 2012 | 1832 | 0.050 |
Why?
|
Southeastern United States | 1 | 2020 | 95 | 0.040 |
Why?
|
Cognition | 2 | 2017 | 6770 | 0.040 |
Why?
|
Contraceptive Agents | 1 | 2021 | 151 | 0.040 |
Why?
|
Health Services Administration | 1 | 2000 | 64 | 0.040 |
Why?
|
Spouses | 1 | 2022 | 286 | 0.040 |
Why?
|
Suicide | 1 | 2010 | 1477 | 0.040 |
Why?
|
Self Care | 1 | 2004 | 786 | 0.040 |
Why?
|
Matched-Pair Analysis | 1 | 1999 | 288 | 0.040 |
Why?
|
Magnetic Resonance Imaging | 3 | 2022 | 35421 | 0.040 |
Why?
|
Morbidity | 2 | 2018 | 1769 | 0.040 |
Why?
|
Drug Therapy, Combination | 1 | 2009 | 6489 | 0.040 |
Why?
|
Carcinoma, Adenosquamous | 1 | 2018 | 68 | 0.040 |
Why?
|
England | 1 | 1999 | 522 | 0.040 |
Why?
|
Physicians' Offices | 1 | 2018 | 58 | 0.040 |
Why?
|
Cholesterol, LDL | 1 | 2007 | 2356 | 0.040 |
Why?
|
Imidazolidines | 1 | 2017 | 39 | 0.040 |
Why?
|
Societies, Medical | 1 | 2010 | 3743 | 0.040 |
Why?
|
Education, Medical, Graduate | 1 | 2010 | 2291 | 0.040 |
Why?
|
Decision Support Techniques | 1 | 2007 | 1956 | 0.040 |
Why?
|
Occult Blood | 1 | 2018 | 176 | 0.040 |
Why?
|
Tosyl Compounds | 1 | 2017 | 113 | 0.040 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2023 | 1375 | 0.040 |
Why?
|
Flutamide | 1 | 2017 | 96 | 0.040 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 1 | 2005 | 949 | 0.040 |
Why?
|
Genes, Tumor Suppressor | 1 | 2022 | 1097 | 0.040 |
Why?
|
Selection Bias | 1 | 1999 | 371 | 0.040 |
Why?
|
Critical Care | 3 | 2016 | 2647 | 0.040 |
Why?
|
Community Health Centers | 1 | 2020 | 430 | 0.040 |
Why?
|
Tooth Loss | 1 | 1998 | 197 | 0.030 |
Why?
|
Outpatient Clinics, Hospital | 1 | 2018 | 392 | 0.030 |
Why?
|
Prostate | 2 | 2018 | 1774 | 0.030 |
Why?
|
Models, Statistical | 1 | 2010 | 5102 | 0.030 |
Why?
|
Eukaryotic Initiation Factor-3 | 1 | 2015 | 49 | 0.030 |
Why?
|
Bipolar Disorder | 1 | 2012 | 5027 | 0.030 |
Why?
|
Injections, Intraperitoneal | 1 | 2015 | 425 | 0.030 |
Why?
|
Radiography | 1 | 2006 | 7023 | 0.030 |
Why?
|
Stress, Psychological | 1 | 2010 | 4245 | 0.030 |
Why?
|
Latin America | 1 | 2015 | 381 | 0.030 |
Why?
|
Anilides | 1 | 2017 | 408 | 0.030 |
Why?
|
Gynecomastia | 1 | 2014 | 88 | 0.030 |
Why?
|
Antipsychotic Agents | 1 | 2007 | 3057 | 0.030 |
Why?
|
Product Surveillance, Postmarketing | 1 | 2018 | 430 | 0.030 |
Why?
|
Documentation | 1 | 2020 | 871 | 0.030 |
Why?
|
Schizophrenia | 1 | 2012 | 6882 | 0.030 |
Why?
|
Disease Progression | 3 | 2015 | 13284 | 0.030 |
Why?
|
Michigan | 1 | 2014 | 350 | 0.030 |
Why?
|
Cesarean Section | 1 | 2022 | 1365 | 0.030 |
Why?
|
Insulin Resistance | 1 | 2006 | 3864 | 0.030 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2008 | 8428 | 0.030 |
Why?
|
Bereavement | 1 | 2016 | 277 | 0.030 |
Why?
|
Hot Flashes | 1 | 2014 | 317 | 0.030 |
Why?
|
Blood Pressure | 1 | 2007 | 8554 | 0.030 |
Why?
|
Sweating | 1 | 2012 | 123 | 0.020 |
Why?
|
Pregnancy Outcome | 1 | 2022 | 2795 | 0.020 |
Why?
|
Blood Cell Count | 1 | 2012 | 403 | 0.020 |
Why?
|
Contraceptives, Oral | 1 | 2013 | 564 | 0.020 |
Why?
|
Watchful Waiting | 1 | 2015 | 492 | 0.020 |
Why?
|
Qualitative Research | 1 | 2019 | 2682 | 0.020 |
Why?
|
Chronic Disease | 1 | 2005 | 9146 | 0.020 |
Why?
|
Sampling Studies | 1 | 2012 | 623 | 0.020 |
Why?
|
Tumor Burden | 1 | 2016 | 1915 | 0.020 |
Why?
|
Multicenter Studies as Topic | 1 | 2015 | 1677 | 0.020 |
Why?
|
Bone Diseases, Metabolic | 1 | 2014 | 417 | 0.020 |
Why?
|
American Cancer Society | 1 | 2010 | 61 | 0.020 |
Why?
|
Lymphatic Diseases | 1 | 2012 | 324 | 0.020 |
Why?
|
Canada | 1 | 2015 | 2065 | 0.020 |
Why?
|
Program Evaluation | 1 | 2018 | 2488 | 0.020 |
Why?
|
Adenocarcinoma | 2 | 2018 | 6364 | 0.020 |
Why?
|
Hospitals, Urban | 1 | 2012 | 499 | 0.020 |
Why?
|
Coronary Artery Disease | 1 | 2009 | 6487 | 0.020 |
Why?
|
Databases as Topic | 1 | 2012 | 475 | 0.020 |
Why?
|
Markov Chains | 1 | 2013 | 969 | 0.020 |
Why?
|
Internship and Residency | 1 | 2010 | 5788 | 0.020 |
Why?
|
Carcinoma, Small Cell | 1 | 2012 | 420 | 0.020 |
Why?
|
Poisson Distribution | 1 | 2011 | 513 | 0.020 |
Why?
|
Treatment Failure | 1 | 2015 | 2618 | 0.020 |
Why?
|
Comparative Effectiveness Research | 1 | 2014 | 681 | 0.020 |
Why?
|
Organizational Culture | 1 | 2013 | 510 | 0.020 |
Why?
|
Deoxycytidine | 1 | 2013 | 826 | 0.020 |
Why?
|
Statistics as Topic | 1 | 2015 | 2373 | 0.020 |
Why?
|
Muscle Proteins | 1 | 2014 | 1159 | 0.020 |
Why?
|
Probability | 1 | 2014 | 2505 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2018 | 5078 | 0.020 |
Why?
|
Respiration, Artificial | 1 | 2020 | 2569 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2016 | 4933 | 0.020 |
Why?
|
Fluorouracil | 1 | 2013 | 1619 | 0.020 |
Why?
|
Treatment Refusal | 1 | 2011 | 421 | 0.020 |
Why?
|
Hospital Administration | 1 | 2012 | 353 | 0.020 |
Why?
|
Metabolic Diseases | 1 | 2014 | 658 | 0.020 |
Why?
|
Vaccination | 1 | 1999 | 3278 | 0.020 |
Why?
|
Guidelines as Topic | 1 | 2014 | 1405 | 0.020 |
Why?
|
Genetic Predisposition to Disease | 1 | 2008 | 17446 | 0.020 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2010 | 780 | 0.020 |
Why?
|
Alzheimer Disease | 1 | 2007 | 8037 | 0.020 |
Why?
|
Informed Consent | 1 | 2012 | 995 | 0.020 |
Why?
|
Urologic Surgical Procedures | 1 | 2008 | 302 | 0.020 |
Why?
|
American Heart Association | 1 | 2010 | 1056 | 0.020 |
Why?
|
Europe | 1 | 2011 | 3339 | 0.020 |
Why?
|
Body Composition | 1 | 2014 | 2401 | 0.020 |
Why?
|
Hospital Mortality | 2 | 2016 | 5317 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2016 | 10943 | 0.010 |
Why?
|
ROC Curve | 1 | 2011 | 3527 | 0.010 |
Why?
|
Thrombolytic Therapy | 1 | 1992 | 2161 | 0.010 |
Why?
|
Employee Performance Appraisal | 1 | 1983 | 87 | 0.010 |
Why?
|
Mastectomy, Modified Radical | 1 | 2002 | 62 | 0.010 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2018 | 4034 | 0.010 |
Why?
|
Endoscopy | 1 | 2012 | 1785 | 0.010 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 1 | 2012 | 1378 | 0.010 |
Why?
|
Myelodysplastic Syndromes | 1 | 2012 | 1352 | 0.010 |
Why?
|
Retirement | 1 | 1983 | 215 | 0.010 |
Why?
|
Electronic Health Records | 1 | 2018 | 4468 | 0.010 |
Why?
|
Child | 2 | 2023 | 77709 | 0.010 |
Why?
|
Weight Loss | 1 | 2012 | 2622 | 0.010 |
Why?
|
Neuropsychological Tests | 1 | 2013 | 6993 | 0.010 |
Why?
|
Adaptation, Psychological | 1 | 2010 | 2576 | 0.010 |
Why?
|
Alendronate | 1 | 1998 | 171 | 0.010 |
Why?
|
Primary Prevention | 1 | 2004 | 1167 | 0.010 |
Why?
|
Diagnosis, Differential | 1 | 2012 | 12959 | 0.010 |
Why?
|
Cholesterol | 1 | 2004 | 2917 | 0.010 |
Why?
|
Osteoporosis, Postmenopausal | 1 | 1998 | 386 | 0.010 |
Why?
|
Infant | 1 | 2013 | 35136 | 0.010 |
Why?
|
Child, Preschool | 1 | 2013 | 41006 | 0.010 |
Why?
|
Double-Blind Method | 1 | 1998 | 12026 | 0.000 |
Why?
|